Brian Cassel J, Kerr Kathleen M, McClish Donna K, Skoro Nevena, Johnson Suzanne, Wanke Carol, Hoefer Daniel
Division of Hematology, Department of Oncology and Palliative Care, School of Medicine, Richmond, Virginia.
Kerr Healthcare Analytics, Mill Valley, California.
J Am Geriatr Soc. 2016 Nov;64(11):2288-2295. doi: 10.1111/jgs.14354. Epub 2016 Sep 2.
To evaluate the nonclinical outcomes of a proactive palliative care program funded and operated by a health system for Medicare Advantage plan beneficiaries.
Observational, retrospective study using propensity-based matching.
A health system in southern California.
Individuals who received the intervention between 2007 and 2014 (n = 368) were matched with 1,075 comparison individuals within each of four disease groups: cancer, chronic obstructive pulmonary disease, heart failure, and dementia. All were known to be dead at the time of the retrospective study, were Medicare Advantage beneficiaries, and had 2 years of usage data before death. Median age at death for each disease group was older than 80.
Home- and clinic-based palliative care (PC) services provided by a multidisciplinary team.
Outcomes included hospital costs, other healthcare costs, readmission rates, hospital admissions and bed days, intensive care unit use in final 30 days of life, and death within 30 days of an admission.
Intervention participants in all four disease groups had less hospital use and lower hospital costs nonintervention participants, which drove lower overall healthcare costs. In the final 6 months of life, healthcare costs for the intervention groups stayed largely the same from month to month, whereas costs for comparison participants increased dramatically.
In the context of an alternative payment model in which the provider was "at risk" of bearing the costs of care, a proactive PC program helped to avoid the escalation in hospital use and costs commonly seen in the final months of life.
评估由一个医疗系统资助并运营的、针对医疗保险优势计划受益人的前瞻性姑息治疗项目的非临床结果。
采用基于倾向得分匹配的观察性回顾性研究。
南加州的一个医疗系统。
2007年至2014年间接受干预的个体(n = 368)在四个疾病组(癌症、慢性阻塞性肺疾病、心力衰竭和痴呆症)中分别与1075名对照个体进行匹配。在回顾性研究时,所有个体均已知死亡,均为医疗保险优势计划受益人,且在死亡前有2年的使用数据。每个疾病组的死亡中位年龄均超过80岁。
由多学科团队提供的基于家庭和诊所的姑息治疗(PC)服务。
结果包括医院费用、其他医疗保健费用、再入院率、住院次数和住院天数、生命最后30天内重症监护病房的使用情况以及入院后30天内的死亡情况。
所有四个疾病组的干预参与者的住院次数和住院费用均低于非干预参与者,这使得总体医疗保健费用降低。在生命的最后6个月,干预组的医疗保健费用每月基本保持不变,而对照参与者的费用则大幅增加。
在提供者承担护理费用“风险”的替代支付模式背景下,前瞻性PC项目有助于避免在生命最后几个月常见的住院次数和费用的增加。